Literature DB >> 11181902

Cleavage of intracellular substrates of botulinum toxins A, C, and D in a mammalian target tissue.

S Kalandakanond1, J A Coffield.   

Abstract

The objective of the current study was to determine whether the intracellular targets that mediate the mechanism of action of botulinum toxin at the mammalian neuromuscular junction are the same as those identified in nontarget tissues. Previous studies of this nature have been limited to nontarget tissues because of the perceived low abundance of neural proteins in a neuromuscular preparation. In the current study we have used differential centrifugation to concentrate neural proteins in a synaptosomal-enriched fraction from the mouse phrenic nerve-hemidiaphragm preparation. Immunoblot detection revealed the presence of discrete immunoreactive bands corresponding to SNAP-25, synaptobrevin II, and syntaxin I in the innervated region of the neuromuscular preparation. The ability of these proteins to serve as botulinum toxin substrates in neuromuscular tissue was determined by measuring toxin-induced proteolysis. Exposure of the intact hemidiaphragm preparation to botulinum serotypes A, C, and D (10(-8) M, 5-6-h exposure) resulted in significant reductions in SNAP-25 (67%), syntaxin I (56%), and synaptobrevin II (72%) immunoreactivity, respectively. The toxin-induced proteolysis was specific for each serotype examined. Collectively, these findings provide direct confirmation that botulinum toxin targets integral components of the molecular machinery mediating neurotransmitter release at the neuromuscular junction. To the best of our knowledge this is the first time that studies of this nature on the intracellular action of botulinum toxin have been extended to a recognized mammalian target tissue preparation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181902

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Modulation of calcium currents is eliminated after cleavage of a strategic component of the mammalian secretory apparatus.

Authors:  Eugene M Silinsky
Journal:  J Physiol       Date:  2005-06-16       Impact factor: 5.182

2.  Selective disruption of the mammalian secretory apparatus enhances or eliminates calcium current modulation in nerve endings.

Authors:  Eugene M Silinsky
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-17       Impact factor: 11.205

3.  Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA .

Authors:  Andrew P-A Karalewitz; Abby R Kroken; Zhuji Fu; Michael R Baldwin; Jung-Ja P Kim; Joseph T Barbieri
Journal:  Biochemistry       Date:  2010-09-21       Impact factor: 3.162

Review 4.  Unique ganglioside binding by botulinum neurotoxins C and D-SA.

Authors:  Abby R Kroken; Andrew P-A Karalewitz; Zhuji Fu; Michael R Baldwin; Jung-Ja P Kim; Joseph T Barbieri
Journal:  FEBS J       Date:  2011-05-31       Impact factor: 5.542

5.  Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons.

Authors:  Julie A Coffield; Xiuzhen Yan
Journal:  J Pharmacol Exp Ther       Date:  2009-04-16       Impact factor: 4.030

6.  Phosphatase Inhibitors Function as Novel, Broad Spectrum Botulinum Neurotoxin Antagonists in Mouse and Human Embryonic Stem Cell-Derived Motor Neuron-Based Assays.

Authors:  Erkan Kiris; Jonathan E Nuss; Stephanie M Stanford; Laura M Wanner; Lisa Cazares; Michael F Maestre; Hao T Du; Glenn Y Gomba; James C Burnett; Rick Gussio; Nunzio Bottini; Rekha G Panchal; Christopher D Kane; Lino Tessarollo; Sina Bavari
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

7.  Studying the differential efficacy of postsymptom antitoxin treatment in type A versus type B botulism using a rabbit spirometry model.

Authors:  Amram Torgeman; Arieh Schwartz; Eran Diamant; Tzadok Baruchi; Eyal Dor; Alon Ben David; Avi Pass; Ada Barnea; Arnon Tal; Amir Rosner; Osnat Rosen; Ran Zichel
Journal:  Dis Model Mech       Date:  2018-09-27       Impact factor: 5.758

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.